Logo

Josh Bilenker

Mar 19, 2015

Josh Bilenker has resigned from Roka Bioscience's board, citing demands on his time and other professional commitments. His resignation is effective immediately. Bilenker, who is the CEO of and a director at Loxo Oncology, joined Roka's board in early 2012 and served on its audit committee.

Breaking News
The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.